Understand the source comparison
SLU PP332 Same as SS-LUP-332: Full Comparison
Mechanism Mitochondrial uncoupling via pH-sensitive proton transport Non-selective mitochondrial uncoupling GLP-1 receptor agonism (appetite suppression, delayed gastric emptying) SLU PP332 increases energy expenditure without appetite reduction. Mechanistical
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mechanism
- Mitochondrial uncoupling via pH-sensitive proton transport
- Non-selective mitochondrial uncoupling
- GLP-1 receptor agonism (appetite suppression, delayed gastric emptying)
- SLU PP332 increases energy expenditure without appetite reduction. Mechanistically distinct from both DNP and GLP-1 pathways
- Metabolic Effect
- 12–18% increase in resting VO₂ (rodent data)
- 20–30% increase in metabolic rate
- 5–10% metabolic increase (secondary to weight loss)
- SLU PP332 produces metabolic elevation between GLP-1 agonists and DNP. Moderate thermogenic effect without DNP's lethality risk
- Therapeutic Index
- ~15× (effective dose to lethal dose ratio)
- <2× (extremely narrow safety margin)
- >100× (very wide safety margin)
- SLU PP332's pH-dependent design improves safety vs DNP but remains experimental. Far riskier than FDA-approved GLP-1 medications
- Half-Life
- 4–6 hours (estimated from rodent PK)
- 36 hours
- ~7 days (semaglutide)
- Short half-life allows rapid dose adjustment but requires multiple daily administrations. Less convenient than weekly GLP-1 injections
- Regulatory Status
- Experimental (no clinical trials)
- Banned for human use (industrial chemical only)
- FDA-approved for obesity and diabetes
- SLU PP332 is research-only. No human safety data, no prescribing pathway, no regulatory oversight outside laboratory settings